文献速递血栓与止血

癌症患者突破性血栓形成的治疗策略

How I treat breakthrough thrombosis in patients with cancer.
PubMed 文献 · Blood · 2026-01-01

本文综述了癌症患者抗凝治疗期间发生突破性血栓(6个月累积发生率5%–8%)的管理策略。确认需影像学对比基线;评估非依从性、药物相互作用、吸收障碍及肝素诱导血小板减少等;治疗证据多来自观察性研究,实践倾向换用或加量低分子肝素。

要点

  • 突破性血栓6个月累积发生率5%–8%,需影像对比基线确认。
  • 评估非依从性、药物相互作用、吸收障碍及HIT等促栓因素。
  • 口服抗凝者换用治疗量低分子肝素,已用者加量25%–33%。

核心结论

  • 癌症患者突破性血栓管理证据有限,主要基于观察性研究。
  • 治疗调整后复发和出血风险仍较高。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 突破性血栓6个月累积发生率为5%至8%。
  • 确认需影像学对比基线,因残留血栓常见。
  • 非依从性常见,可通过用药史和药物水平检测评估。
  • 口服抗凝者需排除药物相互作用和胃肠道吸收障碍。

关键数值与推荐

  • 口服抗凝者换用治疗量低分子肝素。
  • 已用治疗量低分子肝素者剂量增加25%至33%。
  • 低分子肝素剂量不足者增至体重调整治疗量。

临床怎么用

  • 怀疑突破性血栓时先影像对比基线确认。
  • 评估非依从性、药物相互作用、吸收障碍及HIT等。
  • 根据抗凝方案调整治疗:换用或加量低分子肝素。

局限性

  • 治疗策略证据主要来自观察性研究,缺乏随机对照数据。
  • 治疗调整后复发和出血风险仍较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cancer face an increased risk of venous thromboembolism (VTE), and breakthrough thrombosis despite anticoagulation, with a 6-month cumulative incidence of 5% to 8%. The management of these events is challenging. Confirming suspected breakthrough thrombosis requires imaging review, ideally by comparison with postindex baseline studies, because residual thrombus is common and may mimic recurrence. When breakthrough thrombosis is confirmed, several potential contributing factors should be assessed. Nonadherence is common among patients undergoing anticoagulation and should be evaluated through detailed medication history. Measurement of drug-specific plasma levels, when available, may assist in confirming nonadherence. In patients on low-molecular-weight heparin (LMWH), underlying prothrombotic conditions such as heparin-induced thrombocytopenia or acquired antithrombin deficiency must also be considered. For patients receiving oral anticoagulants, drug-drug interactions and impaired gastrointestinal absorption should be excluded. Therapeutic strategies are guided by limited evidence, primarily from observational studies. Current practice generally favors switching to therapeutic LMWH if the patient was on oral anticoagulation, escalating LMWH dosing by 25% to 33% if already on therapeutic LMWH, or increasing LMWH to weight-adjusted therapeutic dose if treatment was subtherapeutic. Despite treatment adjustments, recurrence and bleeding risks remain substantial. In this review, we outline common clinical scenarios of breakthrough thrombosis in patients with cancer and critically appraise the available evidence to inform treatment decisions.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Marx CE, Carrier M. How I treat breakthrough thrombosis in patients with cancer. Blood. 2026. PMID: 41557974. doi:10.1182/blood.2025030790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。